BioNexus Gene Lab Corp
BGLC
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.3M
Close$
$-0.79
133.8% downside
Current Fair Value
133.8% downsideOvervalued by 133.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.30 Million |
|---|---|
| Enterprise Value | $3.19 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.61 |
| Beta | 2.19 |
| Outstanding Shares | 2,417,314 |
Return
| Return on Equity | -35.89% |
|---|---|
| Return on Assets | -32.13% |
| Return on Invested Capital | -35.10% |
Valuation & Multiples
| P/E Ratio | -1.78 |
|---|---|
| PEG | 13.92 |
| Price to Sales | 1.17 |
| Price to Book Ratio | 0.78 |
| Enterprise Value to Revenue | 0.6 |
| Enterprise Value to EBIT | -1.1 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 2.57% |
|---|---|
| Total Invested | $497▼ 99.74% |
| Investors Holding | 2▲ 1.00% |
ESG Score
No data